NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 207 filers reported holding NEKTAR THERAPEUTICS in Q1 2017. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
| Q3 2019 | $3,000 | -75.0% | 160 | -50.8% | 0.00% | – |
| Q2 2019 | $12,000 | -47.8% | 325 | -52.2% | 0.00% | – |
| Q1 2019 | $23,000 | +15.0% | 680 | +9.7% | 0.00% | – |
| Q4 2018 | $20,000 | +1900.0% | 620 | +3000.0% | 0.00% | – |
| Q3 2018 | $1,000 | 0.0% | 20 | 0.0% | 0.00% | – |
| Q2 2018 | $1,000 | 0.0% | 20 | -71.4% | 0.00% | – |
| Q4 2016 | $1,000 | 0.0% | 70 | +25.0% | 0.00% | – |
| Q3 2016 | $1,000 | 0.0% | 56 | 0.0% | 0.00% | – |
| Q2 2016 | $1,000 | -98.7% | 56 | -99.0% | 0.00% | – |
| Q1 2016 | $77,000 | +7600.0% | 5,575 | +9855.4% | 0.00% | – |
| Q4 2015 | $1,000 | -96.8% | 56 | -98.0% | 0.00% | – |
| Q3 2015 | $31,000 | -13.9% | 2,832 | 0.0% | 0.00% | – |
| Q2 2015 | $36,000 | +12.5% | 2,832 | 0.0% | 0.00% | – |
| Q1 2015 | $32,000 | -27.3% | 2,832 | 0.0% | 0.00% | – |
| Q4 2014 | $44,000 | – | 2,832 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |